FDA Approves ZONTIVITYâ„¢ (vorapaxar), First-in-Class PAR-1 Antagonist, for the Reduction of Thrombotic Cardiovascular Events in Patients with a History of Heart Attack or with Peripheral Arterial Disease

[Business Wire] – Merck , known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved ZONTIVITYâ„¢ for the reduction of thrombotic cardiovascular events in patients with a history of heart at more

View todays social media effects on MRK

View the latest stocks trending across Twitter. Click to view dashboard

See who Merck is hiring next, click here to view